Results 121 to 130 of about 25,648 (169)

The use of venetoclax in the treatment of acute lymphoblastic leukemia-a systematic review. [PDF]

Ther Adv Med Oncol
Kowalczyk A, Zarychta J, Zawitkowska J, Lejman M.   +3 more
europepmc   +1 more source

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: Extended phase 3 results from RESONATE-2 [PDF]

, 2018
Bartlett, Nancy L, et al.,
core   +1 more source

Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: a case report and literature review. [PDF]

Ann Hematol
Ng JY, Gullapalli V, Othman J, Talaulikar D.   +3 more
europepmc   +1 more source

[Rapid determination of venetoclax in plasma by ultra performance liquid chromatography-tandem mass spectrometry]. [PDF]

Se Pu
Zhu Y, Ma XL, Yu SL, Qiu L.
europepmc   +1 more source

Novel therapeutic strategies targeting resistance mechanisms in hematologic malignancies: from BCL2 inhibition to immunomodulatory approaches. [PDF]

Front Pharmacol
Han Q, Jiang S, Chen J, Xue L.
europepmc   +1 more source

Venetoclax-based therapy in high-risk patients with relapsed/refractory multiple myeloma harboring t(11;14): a case report and review of the literature. [PDF]

J Med Case Rep
Yin J, Zhou X, Zhong Y.
europepmc   +1 more source

Case Report: Targeting the Achilles' heel of monomorphic epitheliotropic intestinal T-cell lymphoma. [PDF]

Front Oncol
Xue S, Gu HF, Yang F, Zhang W, Liu XY, Sun HP, Cao XY.   +6 more
europepmc   +1 more source

Evaluation of mTOR, NFκB, and BCL-2 Inhibitor Activity In Vitro on Diffuse Large B-Cell Lymphoma Cells. [PDF]

Curr Issues Mol Biol
Majchrzak A, Mańka S, Cebula-Obrzut B, Mędra A, Robak P, Mikulski D, Witkowska M.   +6 more
europepmc   +1 more source

Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review. [PDF]

Adv Ther
Allan JN.
europepmc   +1 more source

RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia. [PDF]

J Exp Clin Cancer Res
Tyagi A, Siddiqui M, Eckstrom A, Kurth I, Takeda S, Sharma P, Borthakur G, Yuan B, Abbas HA, Anand V, Borgman J, Kornblau S, Maiti A, Battula VL.   +13 more
europepmc   +1 more source